SCHEMBL6060877

SCHEMBL6060877

CCOP(=O)(OCC)/C(=C/c1cc(C)c(O)c(OC)c1)c1cccnc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 4/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
EGFR P00533 2/20 0.42
CYP1A1 P04798 3/20 0.41
CYP1A2 P05177 3/20 0.41
CYP1B1 Q16678 3/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
RECQL P46063 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HIF1A Q16665 1/20 0.41
PDGFRB P09619 1/20 0.41
PDGFRA P16234 1/20 0.41
GAA P10253 2/20 0.40
PKM P14618 1/20 0.40
ASF1A Q9Y294 1/20 0.40
ALOX5 P09917 1/20 0.39
PTGS1 P23219 1/20 0.39
PTGS2 P35354 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6061410 0.94 POLB (0.48) POLBMEN1KMT2AEGFRCYP1A1
SCHEMBL6061323 0.84 MEN1 (0.42) POLBMEN1KMT2AEGFRCYP1A1
SCHEMBL6061070 0.83 EGFR (0.43) POLBMEN1KMT2AEGFRCYP1A2
SCHEMBL6061241 0.83 EGFR (0.43) POLBMEN1KMT2AEGFRCYP1A2
SCHEMBL6061244 0.83 EGFR (0.43) POLBMEN1KMT2AEGFRCYP1A2
SCHEMBL6061061 0.81 MAPT (0.39) POLBMEN1KMT2ACYP1A2CYP3A4
SCHEMBL6314520 0.80 LMNA (0.43) MEN1KMT2ASMN1; SMN2GAAMAPT
SCHEMBL6752458 0.80 LMNA (0.43) MEN1KMT2ASMN1; SMN2GAAMAPT
SCHEMBL6061011 0.80 GAA (0.60) POLBMEN1KMT2ACYP1A2CYP3A4
SCHEMBL6061043 0.79 CYP1A1 (0.55) POLBMEN1KMT2ACYP1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1482953-A4 ALPHA-SUBSTITUTED HETEROARYLALKYL PHOSPHONATE DERIVATTIVES ILEX PRODUCTS INC (US) 2006-12-13 EP claimed
US-20050124581-A1 Alpha-substituted heteroarylalkyl phosphonate derivatives PHAN HIEU T (CH) 2005-06-09 US claimed
EP-1482953-A1 ALPHA-SUBSTITUTED HETEROARYLALKYL PHOSPHONATE DERIVATTIVES Ilex Products, Inc. (US) 2004-12-08 EP claimed
WO-2003068240-A1 ALPHA-SUBSTITUTED HETEROARYLALKYL PHOSPHONATE DERIVATTIVES ILEX PRODUCTS, INC. (US) 2003-08-21 WO claimed
EP-1482953-A4 ALPHA-SUBSTITUTED HETEROARYLALKYL PHOSPHONATE DERIVATTIVES ILEX PRODUCTS INC (US) 2006-12-13 EP disclosed
US-20050124581-A1 Alpha-substituted heteroarylalkyl phosphonate derivatives PHAN HIEU T (CH) 2005-06-09 US disclosed
EP-1482953-A1 ALPHA-SUBSTITUTED HETEROARYLALKYL PHOSPHONATE DERIVATTIVES Ilex Products, Inc. (US) 2004-12-08 EP disclosed
WO-2003068240-A1 ALPHA-SUBSTITUTED HETEROARYLALKYL PHOSPHONATE DERIVATTIVES ILEX PRODUCTS, INC. (US) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124581-A1 Alpha-substituted heteroarylalkyl phosphonate derivatives APOB, APOL1, LDLR POLB 1364/4885MEN1 4155/4885KMT2A 3039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.